These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15515031)

  • 21. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.
    Flowers CM; Racoosin JA; Lu SL; Beitz JG
    Mayo Clin Proc; 2003 Jun; 78(6):730-1. PubMed ID: 12934784
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs and valvular heart disease.
    Roth BL
    N Engl J Med; 2007 Jan; 356(1):6-9. PubMed ID: 17202450
    [No Abstract]   [Full Text] [Related]  

  • 25. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
    Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
    J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine agonists and valvular heart disease.
    Kast RE; Altschuler EL
    N Engl J Med; 2007 Apr; 356(16):1677; author reply 1678-80. PubMed ID: 17447278
    [No Abstract]   [Full Text] [Related]  

  • 27. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
    Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
    Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
    Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
    J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hiccups associated with dopamine agonists in Parkinson disease.
    Sharma P; Morgan JC; Sethi KD
    Neurology; 2006 Mar; 66(5):774. PubMed ID: 16534128
    [No Abstract]   [Full Text] [Related]  

  • 30. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
    Krishnaswami A; Albers KB; Fross RD; Jang JJ; Berkheimer SB; Kwai Ben VC; Vandeneeden SK
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):276-80. PubMed ID: 22231899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compulsive singing associated with a dopamine agonist in Parkinson disease.
    Kataoka H; Ueno S
    Cogn Behav Neurol; 2010 Jun; 23(2):140-1. PubMed ID: 20535065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromocriptine use and the risk of valvular heart disease.
    Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
    Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine agonists and valvular heart disease.
    Ziegler JL; Bukhman GY
    N Engl J Med; 2007 Apr; 356(16):1677; author reply 1678-80. PubMed ID: 17447277
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pleural effusion caused by pergolide].
    Salvadó M; Barreiro B; González C
    Arch Bronconeumol; 2009 Jan; 45(1):62-3. PubMed ID: 19186303
    [No Abstract]   [Full Text] [Related]  

  • 35. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.
    Horowski R; Jähnichen S; Pertz HH
    Mov Disord; 2004 Dec; 19(12):1523-4. PubMed ID: 15515006
    [No Abstract]   [Full Text] [Related]  

  • 37. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ
    Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome.
    Worthington A; Thomas L
    Eur J Echocardiogr; 2008 Nov; 9(6):828-30. PubMed ID: 18579494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valvular heart disease in patients taking pergolide.
    Waller EA; Kaplan J; Heckman MG
    Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.